SUTRO BIOPHARMA, INC. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2024-11-13: Disclosure Rule10b51Arr Adopted; Period 2024-07-01..2024-09-30; Value No.
- 2024-11-13: Disclosure Non Rule10b51Arr Adopted; Period 2024-07-01..2024-09-30; Value No.
- 2024-11-13: Disclosure Rule10b51Arr Terminated; Period 2024-07-01..2024-09-30; Value No.
- 2024-11-13: Disclosure Non Rule10b51Arr Terminated; Period 2024-07-01..2024-09-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2024-11-13 10-Q | Rule10b51Arr Adopted | 2024-07-01..2024-09-30 | No | |
| 2024-11-13 10-Q | Non Rule10b51Arr Adopted | 2024-07-01..2024-09-30 | No | |
| 2024-11-13 10-Q | Rule10b51Arr Terminated | 2024-07-01..2024-09-30 | No | |
| 2024-11-13 10-Q | Non Rule10b51Arr Terminated | 2024-07-01..2024-09-30 | No | |
| 2024-04-26 DEF 14A | Pay versus Performance Table | 2023-01-01..2023-12-31 | In accordance with rules adopted by the Securities and Exchange Commission pursuant to Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we provide the following disclosure regarding executive compensation for our principal executive officer (“PEO”) and our oth… | |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: LessGrantDateFairValueOfStockAndOptionAwardsInTheCoveredYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | -$4.58M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: LessGrantDateFairValueOfStockAndOptionAwardsInTheCoveredYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$1.97M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: LessGrantDateFairValueOfStockAndOptionAwardsInTheCoveredYear; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | -$1.07M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: PlusFairValueAtYearEndOfUnvestedStockAndOptionAwardsGrantedInTheCoveredYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $2.61M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: PlusFairValueAtYearEndOfUnvestedStockAndOptionAwardsGrantedInTheCoveredYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | $1.78M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: PlusFairValueAtYearEndOfUnvestedStockAndOptionAwardsGrantedInTheCoveredYear; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $699.01K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: PlusFairValueOfStockAndOptionAwardsGrantedInTheCoveredYearThatVestedInTheCoveredYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $507.57K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: PlusFairValueOfStockAndOptionAwardsGrantedInTheCoveredYearThatVestedInTheCoveredYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | $131.82K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: PlusFairValueOfStockAndOptionAwardsGrantedInTheCoveredYearThatVestedInTheCoveredYear; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $62.10K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: ChangeInFairValueOfUnvestedStockAndOptionAwardsGrantedInPriorYears; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | -$2.01M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: ChangeInFairValueOfUnvestedStockAndOptionAwardsGrantedInPriorYears; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$1.38M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: ChangeInFairValueOfUnvestedStockAndOptionAwardsGrantedInPriorYears; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | -$1.49M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: ChangeInFairValueOfStockAndOptionAwardsFromPriorYearsThatVestedInTheCoveredYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | -$608.34K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: ChangeInFairValueOfStockAndOptionAwardsFromPriorYearsThatVestedInTheCoveredYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$1.91M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: ChangeInFairValueOfStockAndOptionAwardsFromPriorYearsThatVestedInTheCoveredYear; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | -$865.89K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: LessGrantDateFairValueOfStockAndOptionAwardsInTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | -$2.35M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: LessGrantDateFairValueOfStockAndOptionAwardsInTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$556.68K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: LessGrantDateFairValueOfStockAndOptionAwardsInTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | -$1.27M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: PlusFairValueAtYearEndOfUnvestedStockAndOptionAwardsGrantedInTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $1.58M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: PlusFairValueAtYearEndOfUnvestedStockAndOptionAwardsGrantedInTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $527.10K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: PlusFairValueAtYearEndOfUnvestedStockAndOptionAwardsGrantedInTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $1.18M |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: PlusFairValueOfStockAndOptionAwardsGrantedInTheCoveredYearThatVestedInTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $80.18K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: PlusFairValueOfStockAndOptionAwardsGrantedInTheCoveredYearThatVestedInTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $20.65K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: PlusFairValueOfStockAndOptionAwardsGrantedInTheCoveredYearThatVestedInTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $0.00 |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: ChangeInFairValueOfUnvestedStockAndOptionAwardsGrantedInPriorYears; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | -$404.48K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: ChangeInFairValueOfUnvestedStockAndOptionAwardsGrantedInPriorYears; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$858.42K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: ChangeInFairValueOfUnvestedStockAndOptionAwardsGrantedInPriorYears; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $0.00 |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: ChangeInFairValueOfStockAndOptionAwardsFromPriorYearsThatVestedInTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | -$403.99K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: ChangeInFairValueOfStockAndOptionAwardsFromPriorYearsThatVestedInTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$518.29K |
| 2024-04-26 DEF 14A | Adjustment To Compensation | AdjToComp: ChangeInFairValueOfStockAndOptionAwardsFromPriorYearsThatVestedInTheCoveredYear; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $0.00 |
| 2024-04-26 DEF 14A | Adjustment To PEO Compensation Footnote | 2023-01-01..2023-12-31 | All stock option valuations included in “Compensation Actually Paid” values were performed using the Black-Scholes option pricing model in a manner generally consistent with the process used to determine stock option grant date fair values under FASB ASC Topic 718 (refer to our annual report for add… | |
| 2024-04-26 DEF 14A | Named Executive Officers Footnote | 2023-01-01..2023-12-31 | The other NEOs in each covered year were as follows: 2023 - Anne Borgman, Hanspeter Gerber; 2022 - Trevor Hallam, Jane Chung; 2021 - Trevor Hallam, Edward Albini, Jane Chung, Arturo Molina. | |
| 2024-04-26 DEF 14A | Compensation Actually Paid Vs Net Income | 2023-01-01..2023-12-31 | ||
| 2024-04-26 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2023-01-01..2023-12-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |